0000928054-26-000020
SEC filingRevenue up 27% YoY on product sales and PWRtek rental; gross margin improved 410 bps, net income benefited from $10.9M income tax benefit.
Flotek Industries, Inc. describes itself as "an advanced technology-driven, chemical and data analytics company" that provides unique and innovative solutions to domestic and international energy markets. The Company is committed to delivering products and services that maximize customer returns by leveraging chemistry as a common value creation platform.
The Company operates through two segments: Chemistry Technologies (CT) and Data Analytics (DA). The CT segment designs, develops, manufactures, packages, distributes and markets optimized chemistry solutions aimed at improving return on invested capital, lowering operational costs, and providing tangible environmental benefits. Customers include energy-related companies such as ProFrac Services (a related party) and industrial companies. The DA segment delivers real-time measurement information and insights using a proprietary field-deployable, in-line optical near-infrared spectrometer. DA solutions generate revenue through equipment rentals and capital sales, serving oil and gas supermajors, midstream companies, gas processing plants, and hydraulic fracturing service providers. Both segments are supported by the Research & Innovation (R&I) advanced laboratory capabilities.
Key branded products include VERACAL, Verax, XSPCT, and Raman analyzers, which provide real-time compositional data such as vapor pressure, boiling point, API gravity, and BTU content. The Automated Interface Detection Algorithm (AIDA) uses machine learning to detect pipeline interfaces in real-time. Additionally, the Company recently acquired mobile power generation assets to support its power services offering.
The Company uses both direct and indirect sales channels, utilizing in-house sales professionals and contractual agency agreements. Marketing includes trade shows, industry publications, podcasts, and online content. Primary focus is North America, with growing efforts in the Middle East and Latin America. Key customer concentration includes the related party ProFrac Services under a long-term chemistry supply agreement that includes minimum purchase obligations and Contract Shortfall Fees.
The CT segment faces competition from traditional chemical suppliers and wholesalers selling directly. The DA segment competes with other providers of real-time measurement equipment and services. The Company differentiates through superior quality, service, and a competitive cost structure with reliable raw material access.
Strategic priorities include reducing environmental impact across air, water, land, and people; being the collaborative partner for sustainable chemistry and digital analytics; integrating CT and DA innovations to enhance capital efficiency; expanding into utility infrastructure power support and other verticals; and advancing hardware, software, and AI platforms.
As of December 31, 2025, Flotek had approximately 160 total and 158 full-time employees, none covered by collective bargaining. The Company achieved a total recordable incident rate (TRIR) of 0.00 for 2025, reflecting its strong safety culture. Compensation includes competitive wages, annual cash performance bonuses, and comprehensive benefits including health insurance, retirement plans, and employee assistance programs.
For the year ended December 31, 2025, Flotek Industries reported total revenue of $237.3 million, a 26.9% increase compared to $187.0 million in 2024. The growth was primarily driven by a $50.2 million increase in product sales and $16.1 million in PWRtek rental revenue, partially offset by lower Contract Shortfall Fees from ProFrac. Gross profit rose 51.9% to $59.8 million, with gross margin expanding to 25.2% from 21.1% due to higher-margin rental revenue and cost leverage. Operating income increased 90.6% to $23.2 million, and the operating margin improved to 9.8% from 6.5%. Net income surged to $30.5 million from $10.5 million, helped by a $10.9 million income tax benefit from a partial release of the valuation allowance on deferred tax assets.
The Chemistry Technologies segment generated revenue of $209.8 million, up 17.8% YoY, driven by increased product sales to both external and related-party customers, though Contract Shortfall Fees declined. Segment operating income rose 14.3% to $30.4 million, with an operating margin of 14.5%. The Data Analytics segment posted revenue of $27.5 million, up 210% YoY, primarily due to $16.1 million in rental income under the Lease Agreement and higher unit sales. Segment operating income swung to $7.9 million from a $0.9 million loss, achieving a 28.7% margin. Corporate and other costs increased 12% to $15.0 million, driven by severance and stock compensation.
Management expects cash flows from operations, the ProFrac Agreement, and the Lease Agreement to fund near-term obligations. The company secured a $12.5 million equipment credit from ProFrac for Data Analytics capital, likely deployed in 2026. A new power services contract (up to 50 MW) was awarded in March 2026, with deployment expected in Q2 2026. No specific revenue or profit guidance was provided, but the company anticipates continued investment in R&D and new product development. The partial tax valuation allowance release reflects improved profitability, though a substantial allowance remains.
As of December 31, 2025, Flotek held $5.7 million in cash and equivalents, plus $0.1 million in restricted cash. Total available borrowings under the ABL facility stood at approximately $8.0 million, with $3.3 million drawn. Total debt amounted to $46.2 million, consisting of $40.0 million under the PWRtek Note (net of deferred financing costs $39.6 million), $3.3 million on the ABL, and $0.4 million in finance lease liabilities. A deferred tax asset of $29.2 million (net of $43.9 million valuation allowance) now appears on the balance sheet following a $15.5 million partial release of the valuation allowance, supported by a three-year cumulative income position and forecasted income under the ProFrac and Lease Agreements. The company also holds $64.2 million in related-party accounts receivable from ProFrac, reflecting Contract Shortfall Fees.
The most significant contractual commitment is the ProFrac Lease Agreement, which guarantees minimum future lease income of $118.6 million through April 2030, with fixed annual rental payments of $27.4 million for the first five years. The ProFrac Agreement also includes a $12.5 million Equipment Credit (settling 2025 Contract Shortfall Fees) that the company must use to purchase or rent equipment from ProFrac, expected to be utilized in 2026. Additionally, remaining contract asset amortization of $62.7 million will be recognized as reductions to related-party revenue through May 2032, and operating and finance lease liabilities of $7.2 million represent future cash obligations.
The company did not repurchase shares or pay dividends. Capital expenditures totaled $16.2 million, largely driven by the $14.3 million in acquired assets (Leased Equipment) from the PWRtek asset acquisition in April 2025. Debt financing activity included the issuance of a $40.0 million PWRtek Note to fund the acquisition, partially offset by a reduction in ABL borrowings (net payments of $1.5 million). The company prepaid $0.1 million of the remaining PPP loan in full.
The Chemistry Technologies segment generated $209.8 million in total revenue (79.6% of consolidated), with operating income of $30.4 million (14.5% margin). The Data Analytics segment contributed $27.5 million (11.6% of consolidated), driven by $16.1 million in new rental revenue from the Lease Agreement, and delivered operating income of $7.9 million (28.7% margin). Geographically, 95.2% of revenue came from the U.S. ($226.0 million), with the United Arab Emirates representing $10.0 million and other countries $1.4 million.
The Risk Factors section of Flotek Industries' 2025 10-K discloses a broad set of risks, with notable emphasis on the company's outsized dependence on its ProFrac relationships, exposure to U.S. tariff policy, and ongoing commodity price volatility. No risk factors were removed as compared to prior-year filings, but the tariff discussion has been expanded and several risks are quantified more explicitly.
The single most material risk is Flotek's reliance on the ProFrac Agreement and Lease Agreement with affiliates of ProFrac Services. These agreements accounted for 62% of total revenues in both 2025 and 2024, and the Lease Agreement alone represented 6.8% of 2025 revenue. Accounts receivable from ProFrac entities totaled $64.2 million as of year-end. Termination of either agreement — or a failure by ProFrac to meet its obligations — would severely impair liquidity. The company also acknowledges that its ability to raise capital is constrained by this revenue concentration, as lenders and capital markets factor in the single-customer credit risk.
Tax attribute risk was crystallized by the 2023 ownership change, which under Section 382 permanently limits the company's ability to use pre-change NOLs. This could force Flotek to pay U.S. federal income taxes that would otherwise be offset, a structural disadvantage versus competitors with full NOL utilization.
Tariff exposure is newly emphasized. Flotek's Chemistry Technologies segment relies on both domestic and imported chemicals, and its Data Analytics segment uses instruments with foreign components. The company notes that 4.8% of revenues come from outside the U.S., making it vulnerable to retaliatory tariffs. The unpredictability of trade policy (announcements followed by exemptions and pauses) complicates planning and risk mitigation.
Hydraulic fracturing regulation remains a core threat. Most CT segment revenue comes from customers performing fracking. State-level disclosure rules for chemical formulations could expose proprietary chemistry, and any federal restrictions on fracking would directly reduce demand. The DA segment's recent EPA approval for flare monitoring is a positive development, but it is subject to regulatory reversal, and a shift to subscription-based revenue could depress near-term sales.
Climate and ESG pressures are acknowledged as potentially reducing demand for hydrocarbons and limiting access to capital. Unfavorable ESG ratings could further deter investors.
The high customer concentration (76% from top three) extends beyond ProFrac: other large customers operate on short-term purchase orders, making retention critical. Loss of a key customer would have a swift revenue impact.
Supply chain risk is elevated by dependence on sole-sourced components for the Verax measurement system and on commodity chemicals subject to price volatility. The company does not hedge commodity prices and may not be able to pass cost increases to customers.
Cybersecurity is recognized as a material risk, though no incidents have materially affected the company to date. The disclosure references Item 1C's cybersecurity governance structure, but the risk factor notes that insurance coverage may be insufficient.
Conflict of interest between Flotek and ProFrac is explicitly flagged. ProFrac affiliates hold ~61% of common stock, four of seven board seats, and are the largest customer. This creates potential for decisions that benefit ProFrac at the expense of other shareholders.
Thin trading of FTK stock amplifies price volatility and makes large sell orders difficult. The company has no plans to pay dividends, so investors rely solely on price appreciation.
Flotek's 2025 risk profile is dominated by the ProFrac relationship — which simultaneously provides the bulk of revenue and creates concentrated credit, operational, and governance risks. Tariff and regulatory uncertainty add near-term headwinds, while the NOL limitation is a permanent tax drag. The DA segment's regulatory approval offers a growth opportunity, but it is nascent and subject to policy shifts.
CFO of $7.2 million in 2025 exceeded net income of $30.5 million significantly due to large non-cash deferred income tax benefit of $11.2 million (which reduced net income but did not affect cash) and heavy working capital outflows. The primary drag on operating cash was a massive $36.6 million increase in accounts receivable from a related party, partially offset by a $10.2 million increase in accounts payable and inventory reductions of $3.1 million. This suggests the company is extending credit to key customers or funding growth, which weighs on cash conversion.
Capex of $2.0 million (28% of CFO) indicates moderate reinvestment intensity. No free cash flow is explicitly stated; however, CFO minus capex implies approximately $5.2 million of free cash flow, but the large receivable buildup may not be sustainable.
No share repurchases or dividends were paid. Financing activities consumed $3.7 million, primarily from net asset-based loan repayments and tax withholding on equity awards. The effective exchange rate impact reduced cash by $0.2 million. Overall, cash and restricted cash increased $1.3 million to $5.8 million, leaving liquidity modest relative to the revenue scale.